Wave Life Sciences (WVE) Net Income towards Common Stockholders (2014 - 2026)
Wave Life Sciences posted quarterly Net Income towards Common Stockholders of -$26.1 million for Q1 2026, up 44.35% year-on-year from -$18.1 million in Q1 2025, and up 50.94% on a QoQ basis from -$53.2 million in Q4 2025.
Wave Life Sciences (WVE) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$26.1 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 44.35% year-over-year to -$26.1 million; the trailing twelve-month figure through Mar 2026 stood at -$183.6 million (down 63.44% YoY), and the FY2025 full-year result was -$204.4 million, down 110.68% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$26.1 million, up from -$53.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $29.3 million in Q4 2024 and bottomed at -$61.8 million in Q3 2024.
- The 5-year median for Net Income towards Common Stockholders is -$37.8 million (2022), against an average of -$32.2 million.
- Peak annual rise in Net Income towards Common Stockholders reached 279.7% in 2024, while the deepest fall reached 951.9% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$43.7 million in 2022, then jumped by 62.76% to -$16.3 million in 2023, then soared by 279.7% to $29.3 million in 2024, then sank by 281.79% to -$53.2 million in 2025, then jumped by 50.94% to -$26.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$26.1 million (Q1 2026), -$53.2 million (Q4 2025), and -$53.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Wave Life Sciences | 1.32 Bn | 772.50 Mn | - | -26.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.09 Mn |
| Dec 31, 2025 | -53.18 Mn |
| Sep 30, 2025 | -53.85 Mn |
| Jun 30, 2025 | -50.47 Mn |
| Mar 31, 2025 | -46.88 Mn |
| Dec 31, 2024 | 29.25 Mn |
| Sep 30, 2024 | -61.78 Mn |
| Jun 30, 2024 | -32.92 Mn |
| Mar 31, 2024 | -31.56 Mn |
| Dec 31, 2023 | -16.28 Mn |
| Sep 30, 2023 | 7.25 Mn |
| Jun 30, 2023 | -21.10 Mn |
| Mar 31, 2023 | -27.41 Mn |
| Dec 31, 2022 | -43.71 Mn |
| Sep 30, 2022 | -39.00 Mn |
| Jun 30, 2022 | -41.30 Mn |
| Mar 31, 2022 | -37.81 Mn |
| Dec 31, 2021 | -34.79 Mn |
| Sep 30, 2021 | -6.23 Mn |
| Jun 30, 2021 | -38.77 Mn |
| Mar 31, 2021 | -42.46 Mn |
| Dec 31, 2020 | -28.83 Mn |
| Sep 30, 2020 | -33.10 Mn |
| Jun 30, 2020 | -40.53 Mn |
| Mar 31, 2020 | -47.49 Mn |
| Dec 31, 2019 | -56.77 Mn |
| Sep 30, 2019 | -50.73 Mn |
| Jun 30, 2019 | -41.94 Mn |
| Mar 31, 2019 | -44.20 Mn |
| Dec 31, 2018 | -37.89 Mn |
| Sep 30, 2018 | -37.63 Mn |
| Jun 30, 2018 | -35.89 Mn |
| Mar 31, 2018 | -35.24 Mn |
| Dec 31, 2017 | -29.89 Mn |
| Sep 30, 2017 | -25.49 Mn |
| Jun 30, 2017 | -24.60 Mn |
| Mar 31, 2017 | -21.10 Mn |
| Dec 31, 2016 | -18.71 Mn |
| Sep 30, 2016 | -17.54 Mn |
| Jun 30, 2016 | -11.57 Mn |
| Mar 31, 2016 | -7.85 Mn |
| Dec 31, 2015 | -7.10 Mn |
| Sep 30, 2015 | -4.94 Mn |
| Jun 30, 2015 | -3.70 Mn |
| Mar 31, 2015 | -3.47 Mn |
| Dec 31, 2014 | -1.75 Mn |
| Sep 30, 2014 | -1.36 Mn |